1-4 of 4
Xiaohong Han, PhD
Close
Sort by
Journal Articles

CRM1 As a New Therapeutic Target For Non-Hodgkin Lymphoma

Yuankai Shi, MD, PhD, Jianfei Wang, PhD, Xiaohong Han, PhD, Ningning Zhang, MD, Shuai Wang, PhD, Jiarui Yao
Journal: Blood
Blood (2013) 122 (21): 1300.
https://doi.org/10.1182/blood.V122.21.1300.1300
Published: 2013
Journal Articles

Cyclin D1 as a Universally-Expressed Mantle Cell Lymphoma-Associated aTumor Antigen for Immunotherapy

Michael Wang, MD, Luhong Sun, PhD, Jianfei Qian, PhD, Xiaohong Han, PhD, Liang Zhang, PhD, Pei Lin, MD, Qing Yi, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 882.
https://doi.org/10.1182/blood.V112.11.882.882
Published: 2008
Journal Articles

Bortezomib Is Synergistic with Rituximab and Cyclophosphamide in Inducing Apoptosis of Mantle Cell Lymphoma Cells In Vitro and In Vivo.

Liang Zhang, PhD, Yuankai Shi, MD, PhD, Xiaohong Han, PhD, Jing Yang, PhD, Jianfei Qian, PhD, Larry W. Kwak, MD, PhD, Jorge Romaguera, MD, Qing Yi, MD, PhD, Michael Wang, MD
Journal: Blood
Blood (2007) 110 (11): 4514.
https://doi.org/10.1182/blood.V110.11.4514.4514
Published: 2007
Journal Articles

Atiprimod Inhibits Growth of Mantle Cell Lymphoma In Vitro and In Vivo and Induces Apoptosis Via Activation of the Mitochondrial Pathway.

Michael Wang, MD, Liang Zhang, PhD, Xiaohong Han, PhD, Jin Yang, MD, Jianfei Qian, MD, Siqing Wang, MD, Sungyoul Hong, MD, Xiang Zhang, MD, Yuhong Zhou, MD, Jorge Romaguera, MD, Qing Yi, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 2514.
https://doi.org/10.1182/blood.V108.11.2514.2514
Published: 2006